Esomeprazole And Symptomatic Response In Patients With Or Without An Elevated Risk For Non-Steroidal Anti-Inflammatory Drug (NSAID)-Associated GI Damage

AstraZeneca1,220 enrolled

Overview

The purpose of this study is to compare the treatment effect in patients with upper gastro-intestinal complaints with an elevated risk for NSAID-associated GI-damage to those without an elevated risk for NSAID-associated damage (as determined by the treating physician).

Study Type

OBSERVATIONAL

Enrollment

1,220

Conditions

Heartburn

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with upper gastro-intestinal complaints (defined as heartburn and/or regurgitation and/or nausea and/or bloated feeling)and treatment with esomeprazole 20mg once daily is started because of this (consult 1). Upper gastro-intestinal complaints are thought to be related to NSAID use * Patient is using an NSAID\*\* with the following conditions: * NSAID use has started at least one week before 1st consultation and is expected to be continued unchanged during the coming period (at least until consult 2) * NSAID is taken at least 3 days a week (\*\*)OTC or Prescription NSAID (\*\*)Conventional NSAID or COX-2 selective NSAID Exclusion Criteria: * Use of a PPI and/or H2RA in the month preceding the study * A history of reflux disease, not related to NSAID use

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.